| Market Cap | 29.46M | P/E | - | EPS this Y | -41.70% | Ern Qtrly Grth | - |
| Income | -8.76M | Forward P/E | -2.01 | EPS next Y | -23.50% | 50D Avg Chg | -18.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -28.00% |
| Dividend | N/A | Price/Book | 1.10 | EPS next 5Y | - | 52W High Chg | -78.00% |
| Recommedations | 1.70 | Quick Ratio | 6.55 | Shares Outstanding | 69.64M | 52W Low Chg | 14.00% |
| Insider Own | 23.65% | ROA | -39.74% | Shares Float | 48.76M | Beta | 0.77 |
| Inst Own | 13.57% | ROE | -39.00% | Shares Shorted/Prior | 109.39K/278.17K | Price | 0.42 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 126,072 | Target Price | 2.75 |
| Oper. Margin | - | Earnings Date | Feb 5 | Volume | 912,116 | Change | -7.92% |
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.